Evotec
 |
|
| Publicly listed stock corporation | |
| Traded as | : EVT |
| Industry | Biotechnology |
| Founded | 1993 |
| Headquarters | Hamburg, Germany |
|
Key people
|
Werner Lanthaler (CEO) Enno Spillner (CFO) Dr Cord Dohrmann (CSO) Dr Mario Polywka (COO) Prof. Dr Wolfgang Plischke (Chairman of the Supervisory Board) |
|
Number of employees
|
1,017 (06/2016) |
| Website | www.evotec.com |
Werner Lanthaler (CEO) Enno Spillner (CFO) Dr Cord Dohrmann (CSO) Dr Mario Polywka (COO)
Evotec AG is a drug discovery and development partnership company providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors as well as to foundations and not-for-profit organisations. With a pool of highly experienced scientists, state-of-the-art technology platforms, first-class scientific operations and key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases, Evotec aims to develop best-in-class and first-in-class differentiated therapeutics – for collaborators or for its own internal pipeline development.
Evotec, founded in 1993, is a publicly listed stock corporation operating under German law. Since 2009, the Company has been listed in the Prime Standard at Frankfurt Stock Exchange and is a member of the TecDAX index.
Evotec is headquartered in Hamburg, Germany. In addition to Evotec’s site in Hamburg (Germany), major operating sites exist in Abingdon and Manchester (UK), Toulouse (France), Göttingen and Munich (Germany) and South San Francisco, Branford and Princeton (USA). Further offices in Germany, the USA, the UK, France and Japan handle Evotec’s international business development activities.
The Evotec Group employed 1,017 people at the end of June 2016.
Evotec BioSystems GmbH was founded in Hamburg, Germany in 1993. Among the founders were Nobel Laureate Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Schulte, Rudolf Rigler and Charles Weissmann.
In the first years, the Company established collaborations with international Pharma companies like Novartis and SmithKlineBeecham to develop a high-throughput screening system (EVOscreen®. In 1999, Evotec Biosystems went public (Frankfurt Stock Exchange: EVT) and merged one year later with the British company Oxford Asymmetry International plc, which offered chemical services for biotech and Pharma companies and formed Evotec OAI (in 2005 the name changed to Evotec AG ).
In 2002, the Company was divided into two business parts, namely “Discovery and Development Services“ and “Tools and Technologies”. In this year, Evotec Technologies GmbH was founded. In 2006, Evotec Technologies was sold to Perkin Elmer to focus on its core business, the discovery and development of new pharmaceutical drugs. In 2008, Evotec acquired Renovis, an US biotech company and was listed on NASDAQ. One year later, Evotec underwent a change in management and strategy. During 2009, Evotec implemented its “Action Plan to Focus and Grow” encompassing strict cost-cutting and restructuring measures. As a consequence, Evotec voluntarily delisted its American Depository Shares from the NASDAQ stock market to reduce associated costs and to concentrate its share trading on the TecDAX platform, which it re-entered in 2009. Additionally, Evotec took over 70% of Indian Research Support International Limited (RSIPL) and a company providing organic synthesis and a zebrafish screening platform from Summit Corporation.
...
Wikipedia